Dabigatran
Dabigatran Etexilate, Pradaxa (dabigatran) is a small molecule pharmaceutical. Dabigatran was first approved as Pradaxa on 2008-03-17. It has been approved in Europe to treat replacement arthroplasty and venous thromboembolism. The pharmaceutical is active against prothrombin.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| operative surgical procedures | D013514 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dabigatran | ANDA | 2024-10-07 |
| dabigatran etexilate | ANDA | 2024-10-25 |
| pradaxa | New Drug Application | 2024-04-03 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DABIGATRAN ETEXILATE MESYLATE, PRADAXA, BOEHRINGER INGELHEIM | |||
| 2024-12-21 | PED | ||
| 2024-06-21 | I-862, NP | ||
HCPCS
No data
Clinical
Clinical Trials
412 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 7 | 11 | 41 | 105 | 164 |
| Thromboembolism | D013923 | HP_0001907 | — | — | 9 | 15 | 9 | 25 | 58 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | 8 | 10 | 6 | 19 | 43 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 3 | 7 | 8 | 23 | 41 |
| Thrombosis | D013927 | — | — | 1 | 3 | 6 | 8 | 20 | 38 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 2 | 11 | 4 | 19 | 37 |
| Ischemic stroke | D000083242 | — | — | 1 | 2 | 3 | 3 | 17 | 26 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | 1 | 4 | 2 | 9 | 16 |
| Embolism | D004617 | — | — | — | — | 1 | 7 | 7 | 15 |
| Ischemia | D007511 | EFO_0000556 | — | — | 2 | — | 4 | 7 | 13 |
Show 46 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 76 | 1 | 1 | — | — | 77 |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | 3 | — | 2 | 5 |
| Cerebral hemorrhage | D002543 | — | — | — | 1 | 1 | — | 1 | 3 |
| Intracranial thrombosis | D020767 | — | — | — | — | 1 | — | 2 | 3 |
| Hematoma | D006406 | EFO_0010680 | — | — | — | 2 | — | 1 | 3 |
| Recurrence | D012008 | — | — | — | — | 1 | — | 2 | 3 |
| Replacement arthroplasty knee | D019645 | — | — | — | 1 | 2 | — | — | 3 |
| Intracranial sinus thrombosis | D012851 | — | — | — | — | 3 | — | — | 3 |
| Emergencies | D004630 | — | — | — | — | 1 | — | 1 | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | 1 | — | 1 | 2 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | 2 | — | — | 2 | 4 |
| Covid-19 | D000086382 | — | — | 1 | 1 | — | — | 1 | 3 |
| Heart valve prosthesis | D006350 | EFO_0003906 | — | — | 1 | — | — | 1 | 2 |
| Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | — | 1 | — | — | — | 1 |
| Cardiac catheterization | D006328 | — | — | — | 1 | — | — | — | 1 |
| Cadasil | D046589 | Orphanet_136 | I67.850 | — | 1 | — | — | — | 1 |
| Multi-infarct dementia | D015161 | — | F01 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | 4 | 5 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 1 | — | — | — | 4 | 5 |
| Hemostatic disorders | D020141 | — | — | 1 | — | — | — | 4 | 5 |
| Drug interactions | D004347 | — | — | 5 | — | — | — | — | 5 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | 1 | 3 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | 1 | — | — | — | 1 | 2 |
| Interstitial lung diseases | D017563 | HP_0006530 | J84.89 | 1 | — | — | — | 1 | 2 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | — | — | — | 1 | 2 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
Show 21 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative hemorrhage | D019106 | — | — | — | — | — | — | 3 | 3 |
| Arterial occlusive diseases | D001157 | EFO_0009085 | — | — | — | — | — | 2 | 2 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 2 | 2 |
| Therapeutic chemoembolization | D016461 | — | — | — | — | — | — | 2 | 2 |
| Postphlebitic syndrome | D011186 | — | I87.0 | — | — | — | — | 2 | 2 |
| Postthrombotic syndrome | D054070 | EFO_0007452 | I87.0 | — | — | — | — | 2 | 2 |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | — | — | — | 2 | 2 |
| Fibrosis | D005355 | — | — | — | — | — | — | 2 | 2 |
| Blood coagulation tests | D001780 | — | — | — | — | — | — | 2 | 2 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 2 | 2 |
Show 27 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dabigatran |
| INN | dabigatran |
| Description | Dabigatran is an aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism. It has a role as an anticoagulant, an EC 3.4.21.5 (thrombin) inhibitor and an EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor. It is an aromatic amide, a member of benzimidazoles, a carboxamidine, a member of pyridines and a beta-alanine derivative. |
| Classification | Small molecule |
| Drug class | thrombin inhibitors (argatroban type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21 |
Identifiers
| PDB | — |
| CAS-ID | 211914-51-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL48361 |
| ChEBI ID | 70752 |
| PubChem CID | 216210 |
| DrugBank | DB14726 |
| UNII ID | I0VM4M70GC (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Dabigatran
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,949 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dabigatran, Dabigatran etexilate, Pradaxa
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
78,139 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use